Diferencia entre revisiones de «Rivaroxaban»
(Added AF main page link to See Also)
 
(No se muestran 18 ediciones intermedias de 9 usuarios)
Línea 1: Línea 1:
==Administration==
==Administration==
*Type: Anticoagulant, Factor Xa Inhibitor
*Type: [[Anticoagulant]], Factor Xa Inhibitor
*Dosage Forms: 10, 15, 20
*Dosage Forms: 10mg, 15mg, 20mg
*Routes of Administration:
*Routes of Administration:
*Common Trade Names: Xarelto
*Common Trade Names: Xarelto


==Adult Dosing==
==Adult Dosing==
*Thromboembolism/[[stroke]] prophylaxis: 20 mg PO qd
===Thromboembolism/[[stroke]] prophylaxis===
*[[DVT]] Prophylaxis: 10 mg PO qd x35 days; Start: 6-10h post-op once hemostasis established
*20mg PO QD
*[[DVT]]/[[PE]] Prophylaxis, recurrent: 20 mg PO qd
 
*[[DVT]]/[[PE]] Treatment: 20 mg PO qd
===[[DVT]] Prophylaxis===
*10mg PO QD x35 days; Start: 6-10h post-op once hemostasis established
 
===[[DVT]]/[[PE]] Prophylaxis, recurrent===
*20mg PO once daily
 
===[[DVT]]/[[PE]] Treatment===
*15mg twice daily x 21 days if CrCl ≥15<ref>Xarelto https://www.xareltohcp.com/dvt-pe/initial/dosing</ref>
*20mg once daily starting day 22 if CrCl ≥15
 
===[[Atrial fibrillation]] and new stent<ref>Gibson CM et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016 Nov 14.</ref>===
*Rivaroxaban 15 mg/day plus [[clopidogrel]] for 12 months post-stenting just as efficacious to current standard
*Reduces clinically significant bleeds from ~27% to 17% as compared to [[warfarin]] plus DAPT


==Special Populations==
==Special Populations==
Línea 16: Línea 28:
===Renal Dosing===
===Renal Dosing===
*Thromboembolism/[[stroke]] prophylaxis
*Thromboembolism/[[stroke]] prophylaxis
**CrCl 15-50: 15 mg qd; CrCl <15: avoid use
**CrCl 15-50: 15mg QD; CrCl <15: avoid use
*[[DVT]] prophylaxis
*[[DVT]] prophylaxis
**CrCl 30-50: caution advised; CrCl <30: avoid use
**CrCl 30-50: caution advised; CrCl <30: avoid use
Línea 33: Línea 45:
*Hepatic impairment, Child-Pugh Class B or C
*Hepatic impairment, Child-Pugh Class B or C
*Coagulopathy-assoc. hepatic disease
*Coagulopathy-assoc. hepatic disease
*CrCl <30 (DVT prophylaxis, recurrent DVT/PE prophylaxis, DVT/PE tx use)
*CrCl <30 (DVT prophylaxis, recurrent DVT/PE prophylaxis, DVT/PE treatment use)
*CrCl <15 (thromboembolism/stroke prophylaxis use)
*CrCl <15 (thromboembolism/stroke prophylaxis use)
*Acute [[PE]] with hemodynamic instability
*Acute [[PE]] with hemodynamic instability
Línea 41: Línea 53:
===Serious===
===Serious===
*[[Anticoagulant reversal for life-threatening bleeds|Bleeding, severe]]
*[[Anticoagulant reversal for life-threatening bleeds|Bleeding, severe]]
**[[Andexanet alfa]]
*Epidural/[[spinal hematoma]]
*Epidural/[[spinal hematoma]]
*[[Thrombocytopenia]]
*[[Thrombocytopenia]]
Línea 47: Línea 60:
*[[Stevens-Johnson syndrome]]
*[[Stevens-Johnson syndrome]]
*[[Hepatitis]]
*[[Hepatitis]]
===Common===
===Common===
*Bleeding
*Bleeding
*[[Back pain]]
*[[Back pain]]
*[[Pruritus]]
*[[Pruritus]]
*Elevated ALT  
*Elevated ALT
*[[Thrombocytopenia]]
*[[Thrombocytopenia]]


Línea 60: Línea 74:


==Mechanism of Action==
==Mechanism of Action==
*Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa in both the intrinsic and extrinsic coagulation pathways  
*Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa in both the intrinsic and extrinsic coagulation pathways
 
==Indications by Condition==
''The following table is automatically generated from disease/condition pages across WikEM.''
{{#ask:[[Has DrugName::Rivaroxaban]]
|?Has Indication=Indication
|?Has Dose=Dose
|?Has Context=Context
|?Has Route=Route
|?Has Population=Population
|format=table
|headers=plain
|mainlabel=-
|sort=Has Indication
|limit=50
}}


==See Also==
==See Also==
*[[Anticoagulant reversal for life-threatening bleeds]]
*[[Anticoagulant reversal for life-threatening bleeds]]
*[[Andexanet alfa]]
*[[Atrial fibrillation (main)]]


==References==
==References==
<UpToDate, Epocrates>
*UpToDate
*Epocrates
<references/>
 
[[Category:Pharmacology]]
[[Category:Pharmacology]]

Revisión actual - 01:18 25 mar 2026

Administration

  • Type: Anticoagulant, Factor Xa Inhibitor
  • Dosage Forms: 10mg, 15mg, 20mg
  • Routes of Administration:
  • Common Trade Names: Xarelto

Adult Dosing

Thromboembolism/stroke prophylaxis

  • 20mg PO QD

DVT Prophylaxis

  • 10mg PO QD x35 days; Start: 6-10h post-op once hemostasis established

DVT/PE Prophylaxis, recurrent

  • 20mg PO once daily

DVT/PE Treatment

  • 15mg twice daily x 21 days if CrCl ≥15[1]
  • 20mg once daily starting day 22 if CrCl ≥15

Atrial fibrillation and new stent[2]

  • Rivaroxaban 15 mg/day plus clopidogrel for 12 months post-stenting just as efficacious to current standard
  • Reduces clinically significant bleeds from ~27% to 17% as compared to warfarin plus DAPT

Special Populations

Renal Dosing

  • Thromboembolism/stroke prophylaxis
    • CrCl 15-50: 15mg QD; CrCl <15: avoid use
  • DVT prophylaxis
    • CrCl 30-50: caution advised; CrCl <30: avoid use
  • DVT/PE prophylaxis, recurrent
    • CrCl <30: avoid use
  • DVT/PE treatment
    • CrCl <30: avoid use

Hepatic Dosing

  • Avoid Use In:
    • Child-Pugh Class B or C
    • Coagulopathy-assoc. hepatic disease

Contraindications

  • Active major bleeding
  • Hepatic impairment, Child-Pugh Class B or C
  • Coagulopathy-assoc. hepatic disease
  • CrCl <30 (DVT prophylaxis, recurrent DVT/PE prophylaxis, DVT/PE treatment use)
  • CrCl <15 (thromboembolism/stroke prophylaxis use)
  • Acute PE with hemodynamic instability
  • Acute PE requiring thrombolysis or pulmonary embolectomy

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 5-9 hours
  • Metabolism: CYP450
  • Excretion: 66% Urine, 28% Feces

Mechanism of Action

  • Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa in both the intrinsic and extrinsic coagulation pathways

Indications by Condition

The following table is automatically generated from disease/condition pages across WikEM.

IndicationDoseContextRoutePopulation
Atrial fibrillation (main)20 mg daily with evening meal (reduced: 15 mg daily if CrCl 15-50)Anticoagulation (NOAC)POAdult
Pulmonary embolism15 mg PO BID x3 weeks, then 20 mg PO dailyAnticoagulation (DOAC)POAdult

See Also

References

  • UpToDate
  • Epocrates
  1. ↑ Xarelto https://www.xareltohcp.com/dvt-pe/initial/dosing
  2. ↑ Gibson CM et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016 Nov 14.
Obtenido de «https://www.wikem.org/w/index.php?title=Rivaroxaban&oldid=389788»